Psilocybe is a genus of mushrooms containing over 150 species, most of which produce psilocybin, a compound that causes psychedelic effects in humans. These small, unassuming fungi have been used in spiritual ceremonies for thousands of years and are now at the center of modern psychiatric research. They grow on every inhabited continent, in habitats ranging from tropical cattle pastures to temperate forest floors.
How to Recognize Psilocybe Mushrooms
Psilocybe species are often called “little brown mushrooms” or “little white mushrooms,” which hints at the identification challenge they present. Most have a cap that feels sticky or slimy when wet, covered by a thin gelatinous skin that can be peeled away. Their gills produce dark purple-brown to nearly black spore prints, a useful trait for telling them apart from lookalikes.
The most recognizable feature is blue bruising. When the flesh of many Psilocybe species is cut, pinched, or damaged, it turns a distinctive blue-green within seconds. Researchers at Germany’s Friedrich Schiller University identified the chemistry behind this in 2020: when tissue is injured, an enzyme strips a phosphate group from psilocybin to produce psilocin, and a second enzyme then oxidizes the psilocin. The oxidized molecules link together into chains of varying lengths, and this mixture of linked molecules is what produces the blue color. It’s a reliable indicator for many Psilocybe species, though some non-psychoactive mushrooms (like certain boletes) also bruise blue through entirely different chemical pathways.
What Makes Them Psychoactive
The primary active compound is psilocybin, which your body converts into psilocin after ingestion. Psilocin is the molecule that actually produces psychedelic effects by activating serotonin receptors in the brain, particularly a receptor subtype called 5-HT2A. Brain imaging studies have shown that psilocybin doses between 3 and 30 mg occupy up to 72% of these receptors, and the intensity of the experience tracks closely with both receptor occupancy and psilocin levels in the blood.
Psilocybe mushrooms also contain several lesser-known related compounds, including baeocystin, aeruginascin, norpsilocin, and norbaeocystin. Despite early speculation that these might contribute to the psychedelic experience, laboratory testing in mice found that baeocystin does not produce psychedelic-like behavioral effects. Only compounds with the same core chemical structure as psilocin triggered those responses, suggesting psilocybin and its conversion to psilocin are doing most of the heavy lifting.
Timeline of Effects
In controlled clinical settings using oral psilocybin, effects typically begin about 40 to 50 minutes after ingestion, though onset can range from as little as 6 minutes to as long as 90 minutes depending on the person. Effects peak around the 2-hour mark regardless of dose. The total duration of noticeable subjective effects averages about 5.5 to 6.5 hours, with higher doses tending to last slightly longer.
Common Species
Of the 150-plus known species, a handful dominate both wild foraging reports and cultivation.
Psilocybe cubensis is the most widely recognized and cultivated species in the world. First documented in Cuba in 1906, it grows naturally in subtropical regions on the dung of cows and horses, favoring humid river valleys. It’s the species behind familiar cultivated varieties like Golden Teacher, B+, and Penis Envy. Psilocybin concentrations in P. cubensis vary enormously depending on the strain and growing conditions, ranging from roughly 0.2 mg/g to over 11 mg/g of dried material. That tenfold-plus variation means two mushrooms of the same species can deliver wildly different experiences.
Psilocybe semilanceata, commonly called the liberty cap, is the type species that defines the genus. It grows in cool, grassy pastures across Europe and parts of North America, and is one of the most commonly encountered wild Psilocybe species in temperate climates.
Psilocybe azurescens, native to the Pacific Northwest of the United States, is among the most potent known species, with psilocybin and psilocin concentrations reaching up to 17.8 mg/g of dried material. For comparison, that’s several times the concentration found in a typical P. cubensis specimen.
Dangerous Lookalikes
Foraging for Psilocybe mushrooms carries serious risk because several toxic species share similar habitats and appearances. Galerina marginata, sometimes called the deadly Galerina, is a small brown mushroom that grows on decaying wood and contains amatoxins, the same liver-destroying compounds found in death cap mushrooms. It can easily be confused with wood-loving Psilocybe species. The key differences are spore print color (Galerina produces rusty brown spores rather than purple-brown) and the absence of blue bruising, but these distinctions require careful, deliberate examination.
Chlorophyllum molybdites, the false parasol, is another cause of mushroom poisonings. It’s a larger white-capped mushroom with greenish gills that sometimes grows in the same grassy areas where Psilocybe species appear. Panaeolus foenisecii, a common lawn mushroom, is frequently mistaken for Psilocybe species by inexperienced foragers. Reliable identification requires checking multiple characteristics together: cap shape and texture, gill color, spore print color, bruising reaction, and habitat.
Centuries of Indigenous Use
Psilocybe mushrooms have a deep history in Mesoamerican cultures. The Olmec, Zapotec, Maya, and Aztec civilizations all used them in healing rituals and religious ceremonies, referring to them as “teonanácatl,” a Nahuatl word often translated as “flesh of the gods.” These mushrooms were part of a broader tradition of plant-based consciousness alteration that also included peyote cactus and morning glory seeds. Indigenous shamans and healers in parts of Mexico continue to use Psilocybe mushrooms in ritual ceremonies today.
Modern Medical Research
Psilocybin is now being studied as a treatment for depression, particularly in people who haven’t responded to conventional antidepressants. Across clinical trials for treatment-resistant depression, response rates at primary endpoints have ranged from 37% to 71%, with remission rates between 20% and 57%. These are notable numbers for a patient population that, by definition, has already failed other treatments.
A recent pilot trial in treatment-resistant depression found that three of seven participants achieved both response and remission at the primary endpoint, a 43% rate consistent with larger studies. The treatment produced a large effect size for depressive symptoms, and improvements were maintained at longer-term follow-up. Anxiety symptoms, however, did not show the same reliable improvement in that trial. All of this research involves psilocybin administered alongside professional psychotherapeutic support, not the compound alone.
Legal Status
Psilocybin and psilocin remain controlled substances in most countries. The legal landscape is shifting unevenly.
- Oregon legalized psilocybin for supervised mental health treatment in licensed service centers in 2020, with the law taking effect in early 2021.
- Colorado passed the Natural Medicine Health Act in 2022, decriminalizing psilocybin, psilocin, and several other psychedelics for adults 21 and older. The law allows personal growing, possession, and sharing (but not sales) and established licensed “healing centers” for supervised use.
- Australia became the first country to allow authorized psychiatrists to prescribe psilocybin for treatment-resistant depression, effective July 2023. Outside of that narrow medical pathway, possession, cultivation, and sale remain illegal.
- U.S. cities including Seattle, Ann Arbor, Oakland, Santa Cruz, Berkeley, Washington D.C., and several Massachusetts cities have passed local decriminalization measures, though federal law still classifies psilocybin as a Schedule I substance.
In most of the world, including all of the European Union, Canada, and the United Kingdom, psilocybin mushrooms remain illegal to possess, sell, or cultivate. Spores, which do not contain psilocybin themselves, occupy a legal gray area in many jurisdictions.